Xtant Medical Holdings (XTNT) Cost of Revenue (2010 - 2025)

Xtant Medical Holdings (XTNT) has 16 years of Cost of Revenue data on file, last reported at $11.7 million in Q3 2025.

• Cost of Revenue for Q3 2025 came in at $11.7 million, up 1.0% year-over-year; the trailing twelve-month figure through Sep 2025 was $45.8 million (down 6.66% YoY), and the FY2024 annual result was $49.2 million, up 28.03% from the prior year.
• Cost of Revenue grew to $11.7 million in Q3 2025 per XTNT's latest filing, from $11.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $13.6 million in Q4 2023 and troughed at $4.9 million in Q1 2021.
• A 5-year average of $8.9 million and a median of $8.7 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2021 and 2023: Cost of Revenue decreased 24.29% in 2021, then soared 132.75% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $7.1 million in 2021, then dropped by 17.41% to $5.8 million in 2022, then soared by 132.75% to $13.6 million in 2023, then declined by 13.92% to $11.7 million in 2024, then increased by 0.53% to $11.7 million in 2025.
• Business Quant data shows XTNT's Cost of Revenue at $11.7 million in Q3 2025, $11.1 million in Q2 2025, and $11.2 million in Q1 2025.